Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to unclog arteries in heart disease patients

NCT ID NCT07303777

Disease control Sponsor: Atom Therapeutics Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new daily pill called ABP-745 in 200 adults with atherosclerosis (hardening of the arteries from plaque buildup). Participants will take either a low, medium, or high dose of ABP-745 or a placebo for 52 weeks. The main goal is to see if the drug can reduce the amount of plaque in the arteries compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABP-745 (tablet)
What this could lead to
If successful, this could point toward a new daily pill to shrink artery plaque and lower heart attack risk.
What could go wrong
This is an early Phase 2 trial with only 200 people. The drug may not reduce plaque more than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Unless otherwise specified, subjects must meet all of the following criteria at screening: * Diagnosed with coronary at herosclerosis, and coronary angiography. * Male or female at 18-75 years of age (inclusive). * Weight ≥40 kg. * Currently using any oral lipid-lowering therapy. * Able to understand and willing to sign an ICF and comply with study requirements. * A woman or man of childbearing potential agreeing to use medically approved contraceptive methods from the screening until 3 months after the last study dose. Exclusion Criteria: Unless otherwise specified, subjects are excluded from the study if any of the following criteria is met: * History of stroke within the past 6 months. * Uncontrolled arrhythmia within 3 months prior to screening. * Evidence of any active or suspected cancer within 3 years prior to the screening. * Having undergone any major surgery within 3 months prior to the screening or planning to undergo any major surgery during the study. * Presence or suspicion of ongoing of any serious infection. * Human immunodeficiency virus (HIV) infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD Ascvd management Atherosclerosis cardiovascular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    33 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, China

  • Cardiovascular Institute of San Diego INC

    NOT_YET_RECRUITING

    San Diego, California, 91911, United States

  • Cardiovascular Research Foundation of Southern California

    NOT_YET_RECRUITING

    Beverly Hills, California, 90210, United States

  • Cognivus

    NOT_YET_RECRUITING

    Wahroonga, Australia

  • Core Research Group Pty Ltd

    NOT_YET_RECRUITING

    Brisbane, Australia

  • Dalian Second Hospital

    NOT_YET_RECRUITING

    Dalian, China

  • Guangdong Province Hospital

    NOT_YET_RECRUITING

    Guangzhou, China

  • Huashan Hospital Fudan University

    NOT_YET_RECRUITING

    Shanghai, China

  • Jiangsu Province Hospital

    NOT_YET_RECRUITING

    Nanjing, China

  • Jinan Central Hospital

    NOT_YET_RECRUITING

    Jinan, China

  • Nanjing Drum Tower Hospital

    NOT_YET_RECRUITING

    Nanjing, China

  • NovaTrails

    NOT_YET_RECRUITING

    Newcastle, New South Wales, 2290, Australia

  • Peking Union Medical College Hospital

    NOT_YET_RECRUITING

    Beijing, China

  • Peking University First Hospital

    NOT_YET_RECRUITING

    Beijing, China

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, China

  • Renmin Hospital of Wuhan University

    NOT_YET_RECRUITING

    Wuhan, China

  • Shaanxi Provincial People's Hospital

    NOT_YET_RECRUITING

    Xi'an, China

  • Shanghai General Hospital

    NOT_YET_RECRUITING

    Shanghai, China

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, China

  • The Affiliated Hospital of Xuzhou Medical College

    NOT_YET_RECRUITING

    Xuzhou, China

  • The First Affiliated Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, China

  • The First Affiliated Hospital of Xian Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, China

  • The First Affiliated Hospital of Zhejiang University school of medicine

    NOT_YET_RECRUITING

    Hangzhou, China

  • The Lundquist Institute

    NOT_YET_RECRUITING

    Torrance, California, 90502, United States

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, China

  • The Zhongshan Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, China

  • Tianjin General Hospital

    NOT_YET_RECRUITING

    Tianjin, China

  • UniSC Clinical Trials (Brisbane)

    NOT_YET_RECRUITING

    Brisbane, Australia

  • University of the Sunshine Coast Clinical Trials Unit - Morayfield

    NOT_YET_RECRUITING

    Morayfield, Queensland, 4506, Australia

  • Washington University School of Medicine, St.louis

    NOT_YET_RECRUITING

    St Louis, Missouri, 63130, United States

  • Wuxi People's Hospital

    NOT_YET_RECRUITING

    Wuxi, China

  • Xuanwu Hospital Capital Medical University

    NOT_YET_RECRUITING

    Beijing, China

  • Zhejiang Provincial People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.